EBS
Emergent BioSolutions Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 71.56K | $475,495 | n/a | n/a |
| Q2 2026 | 77 | 0 | 32.10M | $268.98M | +5 | −5 |
| Q1 2026 | 79 | +5 | 31.51M | $261.75M | +9 | −4 |
| Q4 2025 | 74 | 0 | 30.66M | $378.98M | n/a | n/a |
| Q3 2025 | 18 | +2 | 16.19M | $142.77M | +2 | n/a |
| Q2 2025 | 13 | 0 | 14.86M | $94.78M | n/a | n/a |
| Q1 2025 | 10 | -1 | 7.86M | $38.21M | n/a | −1 |
| Q4 2024 | 11 | +1 | 7.58M | $72.46M | +1 | n/a |
| Q3 2024 | 9 | 0 | 6.09M | $50.89M | +1 | −1 |
| Q2 2024 | 9 | n/a | 4.41M | $30.11M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 946.30K | n/a | $6.45M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 827.80K | n/a | $5.65M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 556.18K | n/a | $3.79M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 542.81K | n/a | $3.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | AQR Capital Management ✦ | 460.31K | n/a | $3.14M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 6 | Two Sigma Investments ✦ | 446.54K | n/a | $3.05M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 346.35K | n/a | $2.36M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 173.75K | n/a | $1.18M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 113.99K | n/a | $777,439 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 187 holders, 43.00M shares, $335.12M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 17.80K sh · $126,202
Officer · 3.00K sh · $19,590
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology